全文获取类型
收费全文 | 2245篇 |
免费 | 139篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 104篇 |
妇产科学 | 53篇 |
基础医学 | 349篇 |
口腔科学 | 20篇 |
临床医学 | 212篇 |
内科学 | 577篇 |
皮肤病学 | 42篇 |
神经病学 | 245篇 |
特种医学 | 94篇 |
外科学 | 174篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 123篇 |
眼科学 | 59篇 |
药学 | 162篇 |
中国医学 | 3篇 |
肿瘤学 | 143篇 |
出版年
2023年 | 7篇 |
2022年 | 17篇 |
2021年 | 41篇 |
2020年 | 25篇 |
2019年 | 35篇 |
2018年 | 35篇 |
2017年 | 41篇 |
2016年 | 51篇 |
2015年 | 59篇 |
2014年 | 91篇 |
2013年 | 109篇 |
2012年 | 129篇 |
2011年 | 166篇 |
2010年 | 97篇 |
2009年 | 83篇 |
2008年 | 142篇 |
2007年 | 164篇 |
2006年 | 138篇 |
2005年 | 139篇 |
2004年 | 136篇 |
2003年 | 138篇 |
2002年 | 105篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 23篇 |
1998年 | 34篇 |
1997年 | 25篇 |
1996年 | 31篇 |
1995年 | 24篇 |
1994年 | 27篇 |
1993年 | 20篇 |
1992年 | 15篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 11篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 15篇 |
1980年 | 11篇 |
1978年 | 9篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1974年 | 14篇 |
1973年 | 7篇 |
1968年 | 6篇 |
排序方式: 共有2386条查询结果,搜索用时 171 毫秒
51.
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma
下载免费PDF全文
![点击此处可从《Transfusion》网站下载免费的PDF全文](/ch/ext_images/free.gif)
52.
53.
Adverse Events in Mobility‐Limited and Chronically Ill Elderly Adults Participating in an Exercise Intervention Study Supported by General Practitioner Practices
下载免费PDF全文
![点击此处可从《Journal of the American Geriatrics Society》网站下载免费的PDF全文](/ch/ext_images/free.gif)
54.
55.
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept 总被引:9,自引:0,他引:9
Wolff D Roessler V Steiner B Wilhelm S Weirich V Brenmoehl J Leithaeuser M Hofmeister N Junghanss C Casper J Hartung G Holler E Freund M 《Bone marrow transplantation》2005,35(10):1003-1010
Steroid-resistant acute GVHD (aGVHD) following allogeneic hematopoietic stem cell transplantation (alloHSCT) continues to be associated with a high mortality. We report the results of a phase II study of treatment of steroid-resistant aGVHD with the IL-2 receptor antibody daclizumab combined with the TNF-receptor fusion protein etanercept. Treatment consisted of daclizumab 1 mg/kg given i.v. on days 1, 4, 8, 15, 22 and etanercept 16 mg/m(2) s.c. on days 1, 5, 9, 13, 17. A total of 21 patients (age 15-61 years) with steroid-resistant aGVHD after alloHSCT were included in the study. Donor types were HLA-matched related (n=6), HLA-matched unrelated (n=14), and HLA-mismatched unrelated (n=1). Eight patients achieved complete, and six showed partial remission of aGVHD. Seven patients did not respond. Four of 21 patients are currently alive with a median follow-up of 586 (185-1155) days. Three patients died due to relapsed malignancy. Treatment-related mortality was due to infectious complications (n=11) or organ failure due to aGVHD (n=3). In total, 12 patients developed subsequent chronic GVHD. In conclusion, the data demonstrate an acceptable response rate of the combination of daclizumab and etanercept in the treatment of steroid-resistant aGVHD. Nevertheless, long-term mortality due to infectious complications and chronic GVHD remains high. 相似文献
56.
Martin Knaus Dhimitër Rapti Enstela Shukullari Ilir Kusi Rezart Postoli Dashamir Xhaxhiu Cornelia Silaghi Dietmar Hamel Martin Visser Renate Winter Steffen Rehbein 《Parasitology research》2014,113(9):3361-3371
During 2008 to 2011, faecal samples, ear swabs, and ectoparasites obtained by full body search and total body comb were collected from 252 cats originating from the greater Tirana area. Faecal samples were examined using the McMaster and Baermann techniques, and a subset of 58 samples was tested for Giardia-specific antigen using a coproantigen enzyme-linked immunosorbent assay (ELISA). The ear swabs were examined for the presence of parasitic mites. Overall, almost 93 % of the cats were identified harbouring one or more parasites: 59.1 % (95 % confidence interval (CI), 53.0–65.0) and 86.9 % (95 % CI, 82.7–91.1) of the cats tested positive for ecto- or endoparasites, respectively; 53.2 % of the cats had evidence for concomitant ectoparasite infestation and endoparasite infection. For ectoparasite infestation, prevalence was 52.0 % for total fleas (Ctenocephalides felis, 51.2 %; Ctenocephalides canis, 2.0 %; and Leptopsylla segnis, 0.4 %), 8.3 % each for Felicola subrostratus and Otodectes cynotis and 4.0 % for Rhipicephalus sanguineus sensu lato. The most prevalent endoparasites were Toxocara ascarids (48.0 %), followed by Aelurostrongylus lungworms (39.7 %), Capillaria spp. (31.7 %), hookworms (32.9 %), dipylidiid cestodes (27.8 %), Cystoisospora spp. (23.4 %) and taeniid cestodes (2.0 %). One animal was found shedding Pseudamphistomum truncatum eggs. Giardia-specific antigen was detected in 29.3 % of the 58 cats tested. Mixed infections with up to six endoparasites concurrently (excluding Giardia) and mixed infestations with two or three species of ectoparasites were recorded in 73.1 and 22.8 % of the parasite-positive cats, respectively. Cats ≤9 months of age were more frequently tested (p?0.05) positive for Toxocara and Cystoisospora infections than cats >9 months while these cats tested more often (p?0.05) Aelurostrongylus-positive compared with the younger cats. The prevalence of infestation with ectoparasites did not differ between the cats of these two age groups. Given the impact that some of the parasites may have upon animal health as well as the zoonotic potential of some of them, measures should be taken to minimise the transmission of these parasites. 相似文献
57.
58.
59.
Batinic K Höbaus C Grujicic M Steffan A Jelic F Lorant D Hörtenhuber T Hoellerl F Brix JM Schernthaner G Koppensteiner R Schernthaner GH 《Atherosclerosis》2012,222(2):557-563
ObjectiveYKL-40 is secreted by macrophages in atherosclerotic lesions and involved in plaque rupture. YKL-40 is elevated in coronary artery disease, and predicts cardiovascular mortality. Experimental in vivo and in vitro data suggest a role of YKL-40 in tissue remodeling. A disease modulating potency of YKL-40 was not investigated in peripheral arterial disease (PAD).MethodsWe measured YKL-40 in 460 subjects: 316 PAD: 71 normal glucose metabolism (PAD-NGM), 90 pre-diabetes (PAD-PREDM) and 155 diabetes (PAD-DM); 20 diabetes with atherosclerosis but without PAD (AS-DM); 85 diabetes without macro-vascular complications (DM) and 39 healthy controls (CO).ResultsYKL-40 is higher in PAD vs. CO (median [25–75 percentile]: 103 [69–159] vs. 43 [30–80] ng/ml; p < 0.001). In addition, YKL-40 is elevated in DM (p < 0.001), PAD-NGM (p = 0.001), PAD-PREDM (p < 0.001), PAD-DM (p < 0.001) and AS-DM (p = 0.002) compared to CO. Among PAD, YKL-40 is increased in PAD-PREDM (p = 0.001) and PAD-DM (p = 0.01) vs. PAD-NGM. By multivariate regression YKL-40 is significantly associated with age (beta = 0.272), triglycerides (beta = 0.216), aspartate-amino-transferase (beta = 0.177) and c-reactive-protein (beta = 0.178). Underpinning its role YKL-40 was found to be associated with micro-/macroalbuminuria (p = 0.014/p = 008) – a strong remodeling inducer. In addition, YKL-40 was elevated in existence of mediasclerosis (p = 0.008), a remodeling process.ConclusionWe are first to show that YKL-40 is higher in subjects with peripheral arterial disease. YKL-40 was higher in PAD patients with pre-/diabetes. In addition, YKL-40 was associated with the “severity” of generalized atherosclerosis estimated by affected vascular beds. All our findings point towards a role of YKL-40 in the progression/prognosis of patients with PAD and concomitant diabetes. 相似文献
60.
Thimm E Richter-Werkle R Kamp G Molke B Herebian D Klee D Mayatepek E Spiekerkoetter U 《Journal of inherited metabolic disease》2012,35(2):263-268